Cancer treatment for people with inherited mutations
Currently there are no cancer treatments approved specifically for people with a mutation, nor guidelines for treating cancer written specifically for people with a mutation. Consider participating in a clinical trial to help experts learn which treatments work best.
To learn more about standard of care treatment options for specific types of cancer, visit our section on Cancer Treatment by Cancer Type.
Get Support
The following organizations offer peer support services for people with or at high risk for cancer:
- FORCE peer support
- Visit our message boards.
- Once you register, you can post on the Diagnosed With Cancer board to connect with other people who have been diagnosed.
- Sign up for our Peer Navigation Program.
- Users are matched with a volunteer who shares their mutation and situation.
- Join our private Facebook group.
- Find a virtual or in-person support meeting.
- Join a Zoom community group meeting.
- Visit our message boards.
- ZERO-The End of Cancer is a nonprofit organization that provides information and support resources for men with cancer.
updated: 03/08/2023
Related Resources
The following resources focus on cancer.
- FORCE cancer resources:
- Information: cancer treatment
- XRAY reviews: cancer
- Video: What's New in Cancer Treatment?
- Video: Sexuality and Intimacy Issues for Men
- Video play list: cancer
- Blog category: cancer
- Malecare has extensive resources for people with cancer.
- National Comprehensive Cancer Network free patient guides:
updated: 08/06/2022
Open Clinical Trials
The following studies are looking at PARP inhibitors and similar agents for treating people with advanced cancer.
- NCT04592237: Chemotherapy, and for the Treatment of Aggressive Variant Cancer. This study will look at how well the combination of chemotherapy drugs (such as cabazitaxel and carboplatin), a PARP inhibitors (), and an agents (cetrelimab) works for treating people with a rare type of cancer known as aggressive variant cancer (AVPC).
- NCT05005728: XmAb®20717 Alone or in Combination With Chemotherapy or in Patients With Castration-Resistant Cancer. This study will look at the safety and clinical activity of the drug XmAb20717 alone or in combination with standard-of-care anticancer therapies in patients with castration-resistant cancer who have been treated with at least 2 prior lines of treatment.
- NCT03317392: Studying the Medication Given with Radium-223 for Advanced Cancer with Bone . This study is measuring the best dosage for and side effects of the drug combination and radium-223 to treat men with mCRPC that has spread to the bones.
- NCT04497844: Treatment for Castration-Sensitive Cancer and Inherited or Tumor Mutations in Damage Repair Genes (Amplitude). The goal of AMPLITUDE is to see if adding to standard of care hormone therapy (ADT) is safe and more effective than standard of care alone. The study is enrolling people who have castration-sensitive cancer and have an inherited or tumor mutation in one of the following genes involved in damage repair: , , , , FANCA,PALB2, RAD51B and RAD54L.
Other clinical trials for people with cancer can be found here.
updated: 09/11/2023
Open Clinical Trials
The following are studies enrolling people with prostate cancer.
- NCT04404894: Long-Term Registry in Cancer Patients From Diverse Urology Practice Settings Following Prolaris® Testing. This registry will evaluate treatment selection for patients with newly diagnosed, localized cancer following Prolaris testing—a risk estimating test. It will measure the proportion of men who initially select treatment with active surveillance, the time frame between active surveillance selection and any change in treatment, and clinical outcomes.
- NCT03697148: in Evaluating Cancer and Helping Treatment Planning in Patients With Cancer. This study looks at how well a type of known as multiparametric magnetic resonance imaging () works in evaluating cancer and helping treatment planning in patients with cancer.
- NCT04396808: Genomics in Michigan to AdJust Outcomes in canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Cancer. The study is looking at a new ways to use tumor testing and other tools to help patients understand their risk for recurrence and make decisions about their care after prostate cancer.
A number of other clinical trials for patients with prostate can be found here.
updated: 05/27/2023